.avif)
.avif)
Avidity Biosciences Email Format
Biotechnology
・
201-500 employees
・
San Diego, CA, USA
Avidity Biosciences is a biotechnology company developing RNA therapeutics using its proprietary AOC platform to combine antibody targeting with oligonucleotide precision for genetic diseases.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@aviditybio.com
Company Overview
Industry
Biotechnology
Founded
2012
Headquarters
San Diego, CA, USA
Revenue
$10M-$25M
FUNDING Stage
Public
Key Executives
Sarah Boyce (President and Chief Executive Officer), Charles Calderaro III (Chief Technical Officer), Eric Mosbrooker (Chief Commercial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Avidity Biosciences?
Avidity Biosciences uses the first.last format, so Jane Smith would be jane.smith@aviditybio.com.
What diseases does Avidity Biosciences target with its AOC platform?
Avidity Biosciences focuses on rare neuromuscular diseases, with clinical programs targeting myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy using its proprietary Antibody Oligonucleotide Conjugate technology.
How did the Novartis acquisition affect Avidity Biosciences in 2026?
Novartis completed its acquisition of Avidity Biosciences on February 27, 2026, making Avidity an indirect wholly owned subsidiary. Prior to closing, Avidity spun off its early-stage precision cardiology programs into a new independent company called Atrium Therapeutics.
What phase of clinical development is Avidity Biosciences' del-zota program in for Duchenne muscular dystrophy?
Del-zota, also known as delpacibart zotadirsen or AOC 1044, is being evaluated in the Phase 3 SAFARI44 trial for people with Duchenne muscular dystrophy who have mutations amenable to exon 44 skipping, and it holds FDA Breakthrough Therapy Designation.
Who leads Avidity Biosciences as its chief executive in 2026?
Sarah Boyce serves as President and Chief Executive Officer of Avidity Biosciences. You can use Clay to find and verify contact details for Avidity Biosciences leadership if you are building an outreach list targeting the company.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating